CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Material agreement · Agreement ended · Results of operations
- S-3ASR Offering Registration Statement
- 10-K Report Annual Report
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure
- 4 Open-market sale Chief Medical Officer sold 15,162 shares at an average $20.33 ($308,291)
- 4 Open-market sale COFO and Secretary sold 15,162 shares at an average $20.33 ($308,291)
- 4 Open-market sale President and CEO sold 36,916 shares at an average $20.34 ($750,955)
- 4 Open-market sale Director sold 3,339 shares at $20.81 ($69,485)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Grant or award President and CEO acquired 54,180 shares (grant or award)
- 4 Grant or award COFO and Secretary acquired 54,180 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 54,180 shares (grant or award)
Page 6 of 40 · 789 filings